DE602006017373D1 - Madcam-antikörper - Google Patents
Madcam-antikörperInfo
- Publication number
- DE602006017373D1 DE602006017373D1 DE602006017373T DE602006017373T DE602006017373D1 DE 602006017373 D1 DE602006017373 D1 DE 602006017373D1 DE 602006017373 T DE602006017373 T DE 602006017373T DE 602006017373 T DE602006017373 T DE 602006017373T DE 602006017373 D1 DE602006017373 D1 DE 602006017373D1
- Authority
- DE
- Germany
- Prior art keywords
- madcam antibody
- madcam
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69745305P | 2005-07-08 | 2005-07-08 | |
| PCT/IB2006/001923 WO2007007173A2 (en) | 2005-07-08 | 2006-07-05 | Human anti-madcam antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602006017373D1 true DE602006017373D1 (de) | 2010-11-18 |
Family
ID=37637550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602006017373T Active DE602006017373D1 (de) | 2005-07-08 | 2006-07-05 | Madcam-antikörper |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20070009536A1 (de) |
| EP (1) | EP1904531B1 (de) |
| JP (1) | JP2009500390A (de) |
| AR (1) | AR054539A1 (de) |
| AT (1) | ATE483732T1 (de) |
| CA (1) | CA2614314A1 (de) |
| DE (1) | DE602006017373D1 (de) |
| DO (1) | DOP2006000162A (de) |
| ES (1) | ES2351057T3 (de) |
| GT (1) | GT200600297A (de) |
| NL (1) | NL1032132C2 (de) |
| PE (1) | PE20070374A1 (de) |
| TW (1) | TW200740844A (de) |
| UY (1) | UY29653A1 (de) |
| WO (1) | WO2007007173A2 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| SV2006001990A (es) | 2004-01-09 | 2006-01-30 | Pfizer | Anticuerpos contra madcam |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1904100A1 (de) * | 2005-07-11 | 2008-04-02 | Pfizer Limited | Neue kombination von anti-madcam-antikörper und antifibrotischem caspase-hemmer zur behandlung von leberfibrose |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP3646859A1 (de) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| BR112012032579B1 (pt) | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| HUE043540T2 (hu) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben |
| US20150010563A1 (en) * | 2012-02-21 | 2015-01-08 | Massachusetts Eye & Ear Infirmary | Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| EP3685839A1 (de) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP2900265B1 (de) | 2012-09-27 | 2018-05-30 | Biocare Medical, LLC | Anti-uroplakin-ii-antikörper, systeme und verfahren |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| JP6445467B2 (ja) | 2013-02-28 | 2019-01-09 | バイオケア メディカル， エルエルシー | 抗ｐ４０抗体システムおよび方法 |
| WO2015051320A2 (en) | 2013-10-03 | 2015-04-09 | Biocare Medical, Llc | Anti-sox10 antibody systems and methods |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| CA2916283A1 (en) | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
| JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊ 抗体 |
| US20180363000A1 (en) * | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
| SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
| KR20220035333A (ko) * | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010810A1 (en) * | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| MX9706049A (es) * | 1995-02-10 | 1998-02-28 | Leukosite Inc | Adresinas vasculares mucosas y sus usos. |
| EP1724282B1 (de) * | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Verfahren zur Herstellung von nicht-immunogenen Proteinen |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| IL139129A0 (en) * | 1998-05-13 | 2001-11-25 | Genentech Inc | Diagnosis and treatment of hepatic disorders |
| AU776910B2 (en) * | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| SV2006001990A (es) * | 2004-01-09 | 2006-01-30 | Pfizer | Anticuerpos contra madcam |
-
2006
- 2006-07-05 AT AT06795104T patent/ATE483732T1/de not_active IP Right Cessation
- 2006-07-05 EP EP06795104A patent/EP1904531B1/de not_active Not-in-force
- 2006-07-05 JP JP2008520019A patent/JP2009500390A/ja active Pending
- 2006-07-05 ES ES06795104T patent/ES2351057T3/es active Active
- 2006-07-05 WO PCT/IB2006/001923 patent/WO2007007173A2/en not_active Application Discontinuation
- 2006-07-05 PE PE2006000803A patent/PE20070374A1/es not_active Application Discontinuation
- 2006-07-05 CA CA002614314A patent/CA2614314A1/en not_active Abandoned
- 2006-07-05 DE DE602006017373T patent/DE602006017373D1/de active Active
- 2006-07-06 DO DO2006000162A patent/DOP2006000162A/es unknown
- 2006-07-06 UY UY29653A patent/UY29653A1/es not_active Application Discontinuation
- 2006-07-06 AR ARP060102918A patent/AR054539A1/es unknown
- 2006-07-06 GT GT200600297A patent/GT200600297A/es unknown
- 2006-07-07 TW TW095124814A patent/TW200740844A/zh unknown
- 2006-07-07 NL NL1032132A patent/NL1032132C2/nl not_active IP Right Cessation
- 2006-07-10 US US11/484,456 patent/US20070009536A1/en not_active Abandoned
-
2009
- 2009-04-23 US US12/429,154 patent/US7935794B2/en not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,532 patent/US20110165167A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1904531A2 (de) | 2008-04-02 |
| US20070009536A1 (en) | 2007-01-11 |
| CA2614314A1 (en) | 2007-01-18 |
| TW200740844A (en) | 2007-11-01 |
| AR054539A1 (es) | 2007-06-27 |
| WO2007007173A2 (en) | 2007-01-18 |
| US20090214558A1 (en) | 2009-08-27 |
| UY29653A1 (es) | 2007-02-28 |
| EP1904531B1 (de) | 2010-10-06 |
| PE20070374A1 (es) | 2007-05-12 |
| WO2007007173A3 (en) | 2007-05-10 |
| NL1032132A1 (nl) | 2007-01-09 |
| ATE483732T1 (de) | 2010-10-15 |
| NL1032132C2 (nl) | 2007-10-09 |
| GT200600297A (es) | 2007-02-14 |
| JP2009500390A (ja) | 2009-01-08 |
| ES2351057T3 (es) | 2011-01-31 |
| US7935794B2 (en) | 2011-05-03 |
| DOP2006000162A (es) | 2007-01-31 |
| US20110165167A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006017373D1 (de) | Madcam-antikörper | |
| LTC1963368I2 (lt) | Anti-il-17 antikūnai | |
| NO20076607L (no) | TWEAK - bindende antistoff | |
| DK1964852T3 (da) | Anti-ilt7-antistof | |
| NO20071430L (no) | Anti-OX4OL antistoffer | |
| NL1027975A1 (nl) | Antilichamen tegen MAdCAM. | |
| DK3332808T3 (da) | Humaniserede L243-antistoffer | |
| NO20071069L (no) | Anti-CD154-antistoff | |
| NO344963B1 (no) | Humanisert antistoff | |
| DK2194043T3 (da) | Fremgangsmåder | |
| DK2301961T4 (da) | Sclerostin-epitoper | |
| ATE408603T1 (de) | Pyrazolylcarboxanilide | |
| CR9974A (es) | Gavión | |
| CY2013046I1 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
| DE602006008259D1 (de) | Siloxaneinkapselungen | |
| DE602006012066D1 (de) | Daraus | |
| DE502006005768D1 (de) | Hydrolysestabilisatorformulierungen | |
| BRPI0509495A2 (pt) | anticorpo humanizado | |
| ATE485368T1 (de) | Hiv - impfung | |
| DE102005052834B8 (de) | Punktschweißklebverbindung | |
| DK1812475T3 (da) | Immunglobulinfraktioner | |
| AT501523A3 (de) | Estrich | |
| DE102006033170A8 (de) | Einfassnähmaschine | |
| DK1931573T3 (da) | Lukke | |
| AT501968A3 (de) | Mitführhilfe |